YM Bioscience's EGFR-targeting Drug Goes Into Phase III Trials In Singapore
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - National Cancer Centre of Singapore will sponsor YM Bioscience's nimotuzumab for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck, the company recently announced
You may also be interested in...
Merck Serono Increases Oncology Medical Representatives To Expand Japanese Market
With the recent market launch of colon cancer drug Erbitux (cetuximab), German drug maker Merck Serono plans to add 20 to 40 oncology medical representatives in three years in Japan. Merck Serono currently has 60 oncology MRs in Japan. Merck Serono's president estimated that as colon cancer will likely top cancer cases in Japan by 2020, Erbitux could become a blockbuster drug. (Click here for more - Japanese language
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
Need a specific report? 1000+ reports available
Buy Reports